Advertisement

Topics

Latest "Jagged Peak Announces Financial Results Second Quarter 2015" News Stories

22:07 EST 18th December 2018 | BioPortfolio

Here are the most relevant search results for "Jagged Peak Announces Financial Results Second Quarter 2015" found in our extensive news archives from over 250 global news sources.

More Information about Jagged Peak Announces Financial Results Second Quarter 2015 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Jagged Peak Announces Financial Results Second Quarter 2015 for you to read. Along with our medical data and news we also list Jagged Peak Announces Financial Results Second Quarter 2015 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Jagged Peak Announces Financial Results Second Quarter 2015 Companies for you to search.

Showing "Jagged Peak Announces Financial Results Second Quarter 2015" News Articles 1–25 of 35,000+

Tuesday 18th December 2018

Helsinn Healthcare SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryHelsinn Healthcare SA Helsinn Healthcare, a subsidiary of Helsinn Holding SA is a cancer care company that offers oncology products and therapies. The company offers products in therapeutic areas of pain and inflammation, cancer care and gastroenterology. Its products comprise Aloxi, Gelclair, Akynzeo, Nimesulide, KleanPrep and laxaclear. The company offers research and development programs...


EU5 Hydrocephalus Shunting Procedures Outlook to 2025 [Report Updated: 01122018] Prices from USD $3396

EU5 Hydrocephalus Shunting Procedures Outlook to 2025SummaryGlobalData's new report, EU5 Hydrocephalus Shunting Procedures Outlook to 2025, provides key procedures data on the EU5 Hydrocephalus Shunting Procedures. The report provides procedure volumes within market segments New Hydrocephalus Shunts Procedures and Revision Hydrocephalus Shunts Procedures.The data in the report is derived from dyn...

Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts


Australia Crown and Bridge Procedures Outlook to 2025 [Report Updated: 01092018] Prices from USD $2546

Australia Crown and Bridge Procedures Outlook to 2025SummaryGlobalData's new report, Australia Crown and Bridge Procedures Outlook to 2025, provides key procedures data on the Australia Dental Crown and Bridge Procedures. The report provides procedure volumes within market segment Dental Crown and Bridge Procedures.The data in the report is derived from dynamic market forecast models. GlobalData ...

MOD Resources (MOD) - Discoveries made, exploration concept validated

Edison Investment Research - Mining - MOD Resources: MOD Resources (MOD) is a copper-silver exploration and development company with a substantial ground holding in the Kalahari Copper Belt, Botswana. The company has been very successful with its regional exploration concept, which has led to the discovery and drill-out of the significant T3 copper-silver deposit and the delineation of a prelimina...

Alfa Wassermann SpA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryAlfa Wassermann SpA Alfa Wassermann, a subsidiary of AlfaSigma SpA is a pharmaceutical company which produces and distributes drugs for human health. The company provides new discoveries in medicine, biology and genomics. Alfa Wassermann finds solutions for paradox treatment. The company offers self meditation products for sore throat, headaches, and muscle and joint pain treatments. It als...

Canadian Cancer Trials Group Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryCanadian Cancer Trials Group CCTG, is a subsidiary of Cancer Research Institute at Queen's University, is a contract research organization that conducts clinical trials. The company conducts trials for the development of new drugs and therapies for the treatment of various diseases. It provides services for cancer therapy, supportive care and prevention. CCTG offers clinical trials for prod...

Martindale Pharmaceuticals Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11122018] Prices from USD $250

SummaryMartindale Pharmaceuticals Ltd Martindale, a subsidiary of Cardinal Health Inc is a pharmaceutical company that offers formulations. The company provides hospitalinitiated medicines in emergency medicine and differentiated products in complex neurological conditions,opioid addiction and paediatric cardiology. It focuses on emergency care drugs, hospital initiated medicines, opioid addiction...

Akaal Pharma Pty Ltd Announces Licensing Agreement for its First-in-Class, Topical Spingosine-1-Phosphate-1 (S1P1) Receptor Modulator for Atopic Dermatitis and Psoriasis

Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has entered into a licensing agreement for Akaal Pharma’s First-in-Class, topical Spingosine-1-Phosphate-1 (S1P1) modulator, AKP-11, with Boston Pharmaceuticals, Inc. (Boston Pharmaceuticals). AKP-11 is a differentiated S1P1 modulator, which potentially has clinical applications in a number ...

Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization

Deal Valued at Potential $160 Million plus Royalties, including $5 Million in Upfront Payments and $35 Million in Equity Investment Shionogi Gains Regional License to Alzheimer’s Drug Candidate for Japan, Korea and Taiwan Collaboration to Accelerate BPN14770 Clinical Development in Fragile X Syndrome and Early...

Quidel Receives CE Mark for Point-of-Care Sofia® 2 Lyme+ Fluorescent Immunoassay for Use with Sofia 2 Instrument

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received CE Mark to market Quidel’s Sofia 2 Lyme+ FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human Ig...

Cellular Dynamics International Inc Medical Equipment Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryCellular Dynamics International Inc CDI, a subsidiary of Fujifilm Holdings Corp is a biotechnology company that develops and manufactures fully functioning human cells in industrial quantities to precise specifications. The company's products include icell cardiomyocytes, icell endothelial cells, icell hepatocytes, icell neurons, icell prototypes and mycell products. It also offers Mycell p...

Takeda is going to start trading in the U.S. on Christmas Eve. h/t @DShaywitz https://www.businesswire.com/news/home/20181218005892/en/Takeda-Announces-Listing-American-Depositary-Shares-New …

Takeda is going to start trading in the U.S. on Christmas Eve. h/t @DShaywitz https://www.businesswire.com/news/home/20181218005892/en/Takeda-Announces-Listing-American-Depositary-Shares-New …

STERIS to Present at the J.P. Morgan Healthcare Conference

DERBY, U.K.  - December 18, 2018 - STERIS plc (NYSE: STE) ("STERIS" or the "Company") announced that it will participate in the J.P. Morgan Healthcare Conference on Monday, January 7, 2019.   Walt Rosebrough, STERIS's President and CEO, will present at 3:00 p.m. Pacific Time. A simultaneous webcast and replay of the Company's presentation will ...

Civitas Solutions Enters into Definitive Merger Agreement to Be Acquired by Centerbridge for $17.75 Per Share in Cash

Civitas Solutions, Inc. (“Civitas” or the “Company”) (NYSE: CIVI) today announced that it has entered into a definitive merger agreement to be acquired by funds advised by Centerbridge Partners, L.P. (“Centerbridge”). Under the terms of the agreement, Centerbridge will acquire all outstanding shares of Civitas common stock for $17.75 in cash pe...

Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange

ADSs Will Trade Under the Ticker Symbol “TAK” NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the listing ...

Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq

Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq PARIS, FRANCE - December 18, 2018 - Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018, after market close. Sanofi's ADSs are expected to begin trading as a...

Greenberg Traurig’s Lori Cohen Selected as a 2018 Law360 Life Sciences MVP

Hard-hitting attorney Lori G. Cohen, co-chair of the Global Litigation Practice at Greenberg Traurig, LLP, as well as chair of the firm's Trial Practice Group and its Pharmaceutical, Medical Device & Health Care Litigation Practice, has been selected by Law360 as a 2018 Life Sciences MVP attorney. ATLANTA (PRWEB) December 18, 2018 Hard-hitting attorney Lori G. Cohen, co-chair of the Globa...

Jake Hesketh makes Burton Albion history at expense of Middlesbrough – The Guardian

Jake Hesketh makes Burton Albion history at expense of Middlesbrough The GuardianCarabao Cup: Burton Albion win 1-0 at Middlesbrough to reach semi-finals BBC SportTony Pulis 'gutted' after Burton defeat but singles out one Middlesbrough player for praise Gazette LiveCarabao Cup quarter-finals LIVE: Leicester face Man City as Middlesbrough host Burton Albion The SunMiddlesbrough 0-1 Burton Albi...

ARANZ Medical Raises NZ$5mil New Equity Financing

CHRISTCHURCH, New Zealand, Dec. 18, 2018 /PRNewswire/ -- ARANZ Medical Limited announces the closing of a NZ$5million equity financing. Bruce Davey, ARANZ Medical CEO says, "I'm delighted to announce this investment in our company. Our imaging solutions help improve clinical outcomes for many people with chronic skin conditions, and we are dedicated to delighting our practitioners and patien...

Manchester City rely on penalties to beat Leicester in Carabao Cup – The Guardian

Manchester City rely on penalties to beat Leicester in Carabao Cup The GuardianCarabao Cup gallery: City are spot on! Manchester City FCLeicester City 1-1 Manchester City (1-3 pens) BBC SportLeicester City 1-1 Manchester City (Man City win 3-1 on pens): Carabao Cup quarter-final – as it happened The GuardianLeicester City winning the Carabao Cup would be 'a great finale', says Christian Fuch...

Lighthouse Health Plan Launches Operations as a Locally-Based, Doctor-Led Medicaid Health Plan

Headquartered in Pensacola, Fla., Lighthouse Health Plan is a community-based health insurance plan created and run by doctors. Lighthouse will begin providing Medicaid coverage to beneficiaries in Florida Medicaid Regions 1 and 2 beginning February 1, 2019, subject to the Agency for Health Care Administration’s (AHCA) approval. PENSACOLA, Fla. (PRWEB) December 18, 2018 Today, Lighthouse Health...

Stago Releases a New Educational Webinar on Validation and Verification of Clinical Coagulation Assays and Instrumentation in a Multisite Hospital Network

On January 15, a new webinar by Jana Gausman, MT(ASCP), will be released at Stago EdVantage Virtual University. Attendees will learn about the responsibility of the laboratory during the validation and verification process for newly acquired instrumentation, along with strategies for ensuring continuous quality of laboratory testing results on a daily basis. Coagulation testing applications will b...

Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019. Ligand expects revenue in 2019 to be at least $212 million, with up to an additional $40 million of potential milestone and license payments. Approximately two thirds of the $212 million of revenue is expected to be royalty revenue, and the remainder is expected t...

South Korea Respiratory Device Accessories Market Outlook to 2025 [Report Updated: 03102018] Prices from USD $4246

South Korea Respiratory Device Accessories Market Outlook to 2025SummaryGlobalData's new report, South Korea Respiratory Device Accessories Market Outlook to 2025, provides key market data on the South Korea Respiratory Device Accessories market. The report provides value, in millions of US dollars, volume in units and average prices USD within market segments Aerosol Masks, CardioPulmonary Resus...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks